Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DESTINY-Lung03
NL-OMON50973Phase 1Not yet recruiting
- Sponsor
- AstraZeneca
- Start
- Feb 2021
- Modality
- Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of trastuzumab deruxtecan, durvalumab, cisplatin, carboplatin and pemetrexed in non-small cell lung cancer (NSCLC) (8 arms), sponsored by AstraZeneca. Primary endpoint: Safety, tolerability, and RP2D determination. Planned start Feb 2021; status: not yet recruiting.
02
Drugs
trastuzumab deruxtecandurvalumabcisplatincarboplatinpemetrexed
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NL-OMON50973.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON50973.